https://www.selleckchem.com/pr....oducts/telotristat-e
Patients with COVID-19 who develop severe acute respiratory distress syndrome (ARDS) can have symptoms that rapidly evolve to profound hypoxaemia and death. The efficacy of extracorporeal membrane oxygenation (ECMO) for patients with severe ARDS in the context of COVID-19 is unclear. We aimed to establish the clinical characteristics and outcomes of patients with respiratory failure and COVID-19 treated with ECMO. This retrospective cohort study was done in the Paris-Sorbonne University Hospital Network, c
Like
Comment
Share
